Abstract
As STAT3 has been validated as an anticancer target, its inhibitors have been shown to possess therapeutic promise for the treatment of human cancers. To identify novel and selective STAT3 inhibitors, a virtual screening based on the STAT3 SH2 domain was performed and a small molecule, 2-phenylquinoline-4-carboxylic acid (5a), with an inhibition constant Ki value of 17.53 μM to STAT3 was discovered. On this basis, the derivatives of 5a including esters, amides and dimers were synthesized. The bioactivity and inhibitory selectivity of the derivatives were assayed using human breast cancer cell lines, MDA-MB-468 and MCF-7. Among the derivatives, 5c and 9b showed the most potent inhibitory activity with a good selectivity, and also inhibited STAT3 protein level of MDA-MB-468 cells. The results demonstrated a successful application of virtual screening for lead discovery. Compound 9b might be an effective STAT3 inhibitor lead for the further development of antitumor agents.
Keywords: 2-Phenyl quinoline-4-carboxylic acid, Breast cancer cell lines, Quinoline, SH2 domian, Small molecule inhibitor, STAT3
Letters in Drug Design & Discovery
Title:Design, Synthesis and Evaluation of Quinoline-based Small Molecule Inhibitor of STAT3
Volume: 10 Issue: 5
Author(s): Zhi-Bing Shi, Lei Zhang, Zheng-Yang Bin, Xiang-Rong Cao, Zhu-Nan Gong and Jian-Xin Li
Affiliation:
Keywords: 2-Phenyl quinoline-4-carboxylic acid, Breast cancer cell lines, Quinoline, SH2 domian, Small molecule inhibitor, STAT3
Abstract: As STAT3 has been validated as an anticancer target, its inhibitors have been shown to possess therapeutic promise for the treatment of human cancers. To identify novel and selective STAT3 inhibitors, a virtual screening based on the STAT3 SH2 domain was performed and a small molecule, 2-phenylquinoline-4-carboxylic acid (5a), with an inhibition constant Ki value of 17.53 μM to STAT3 was discovered. On this basis, the derivatives of 5a including esters, amides and dimers were synthesized. The bioactivity and inhibitory selectivity of the derivatives were assayed using human breast cancer cell lines, MDA-MB-468 and MCF-7. Among the derivatives, 5c and 9b showed the most potent inhibitory activity with a good selectivity, and also inhibited STAT3 protein level of MDA-MB-468 cells. The results demonstrated a successful application of virtual screening for lead discovery. Compound 9b might be an effective STAT3 inhibitor lead for the further development of antitumor agents.
Export Options
About this article
Cite this article as:
Shi Zhi-Bing, Zhang Lei, Bin Zheng-Yang, Cao Xiang-Rong, Gong Zhu-Nan and Li Jian-Xin, Design, Synthesis and Evaluation of Quinoline-based Small Molecule Inhibitor of STAT3, Letters in Drug Design & Discovery 2013; 10 (5) . https://dx.doi.org/10.2174/1570180811310050009
DOI https://dx.doi.org/10.2174/1570180811310050009 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Purinergic Signaling and Energy Homeostasis in Psychiatric Disorders
Current Molecular Medicine New N’-Arylidene-2-[(4-Nitrophenyl)Piperazın-1-yl]Acetohydrazide Derivatives: Synthesis and Anticancer Activity Investigation
Letters in Drug Design & Discovery Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
Current Pharmaceutical Design Regulation of Innate Immune Responses in the Central Nervous System
CNS & Neurological Disorders - Drug Targets An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth
Anti-Cancer Agents in Medicinal Chemistry Non-Homologous DNA End Joining in Anticancer Therapy
Current Cancer Drug Targets Soft Matter Assemblies as Nanomedicine Platforms for Cancer Chemotherapy: A Journey from Market Products Towards Novel Approaches
Current Topics in Medicinal Chemistry The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets Patent Selections :
Recent Patents on CNS Drug Discovery (Discontinued) Blockage of Autophagy in C6 Glioma Cells Enhanced Radiosensitivity Possibly by Attenuating DNA-PK-Dependent DSB Due to Limited Ku Nuclear Translocation and DNA Binding
Current Molecular Medicine Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
Current Pharmaceutical Biotechnology Genomic Context Vectors and Artificial Chromosomes for Cystic Fibrosis Gene Therapy
Current Gene Therapy Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies
Current Pharmaceutical Design Immunologic Diseases and Brain Tumors
Inflammation & Allergy - Drug Targets (Discontinued) Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy
Current Cancer Drug Targets The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets Angiogenesis in Glioblastoma Multiforme: Navigating the Maze
Anti-Cancer Agents in Medicinal Chemistry Cytosine Methyltransferases as Tumor Markers
Current Genomics